Monte Rosa Therapeutics (GLUE) Leases (2023 - 2025)
Monte Rosa Therapeutics (GLUE) has 3 years of Leases data on record, last reported at $25.1 million in Q3 2025.
- For Q3 2025, Leases fell 8.4% year-over-year to $25.1 million; the TTM value through Sep 2025 reached $25.1 million, down 8.4%, while the annual FY2024 figure was $26.8 million, 6.86% down from the prior year.
- Leases reached $25.1 million in Q3 2025 per GLUE's latest filing, down from $25.7 million in the prior quarter.
- Across five years, Leases topped out at $30.5 million in Q1 2023 and bottomed at $25.1 million in Q3 2025.
- Average Leases over 3 years is $27.9 million, with a median of $27.9 million recorded in 2024.
- Peak YoY movement for Leases: fell 6.86% in 2024, then decreased 8.4% in 2025.
- A 3-year view of Leases shows it stood at $28.8 million in 2023, then fell by 6.86% to $26.8 million in 2024, then decreased by 6.58% to $25.1 million in 2025.
- Per Business Quant database, its latest 3 readings for Leases were $25.1 million in Q3 2025, $25.7 million in Q2 2025, and $26.3 million in Q1 2025.